These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7506690)

  • 1. In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins.
    Tuerk C; MacDougal-Waugh S
    Gene; 1993 Dec; 137(1):33-9. PubMed ID: 7506690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using in vitro selection to direct the covalent attachment of human immunodeficiency virus type 1 Rev protein to high-affinity RNA ligands.
    Jensen KB; Atkinson BL; Willis MC; Koch TH; Gold L
    Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12220-4. PubMed ID: 8618873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of an in vitro-selected RNA ligand to the HIV-1 Rev protein.
    Jensen KB; Green L; MacDougal-Waugh S; Tuerk C
    J Mol Biol; 1994 Jan; 235(1):237-47. PubMed ID: 8289245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.
    Tiley LS; Madore SJ; Malim MH; Cullen BR
    Genes Dev; 1992 Nov; 6(11):2077-87. PubMed ID: 1427073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.
    Tuerk C; MacDougal S; Gold L
    Proc Natl Acad Sci U S A; 1992 Aug; 89(15):6988-92. PubMed ID: 1379730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory RNA ligand to reverse transcriptase from feline immunodeficiency virus.
    Chen H; McBroom DG; Zhu YQ; Gold L; North TW
    Biochemistry; 1996 May; 35(21):6923-30. PubMed ID: 8639644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins.
    Pritchard CE; Grasby JA; Hamy F; Zacharek AM; Singh M; Karn J; Gait MJ
    Nucleic Acids Res; 1994 Jul; 22(13):2592-600. PubMed ID: 8041622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV gene regulatory proteins tat and rev and their interactions with synthetic RNA.
    Asseline U; Grasby J; Hamy F; Iwai S; Mann DA; Pritchard C; Karn J; Gait MJ
    Nucleic Acids Symp Ser; 1993; (29):113-4. PubMed ID: 7504239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.
    Southgate C; Zapp ML; Green MR
    Nature; 1990 Jun; 345(6276):640-2. PubMed ID: 2190099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [RNA ligands for HIV proteins].
    Iwai S
    Tanpakushitsu Kakusan Koso; 1995 Jul; 40(10):1430-7. PubMed ID: 7568944
    [No Abstract]   [Full Text] [Related]  

  • 12. Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing.
    Puttaraju M; Been MD
    Nucleic Acids Symp Ser; 1995; (33):152-5. PubMed ID: 8643355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection.
    Guillon C; Stankovic K; Ataman-Onal Y; Biron F; Verrier B
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1283-92. PubMed ID: 17209772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-sequence-mediated gene regulation in HIV-1.
    Cullen BR
    Infect Agents Dis; 1994; 3(2-3):68-76. PubMed ID: 7812657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing.
    Puttaraju M; Been MD
    Nucleic Acids Symp Ser; 1995; (33):49-51. PubMed ID: 8643395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tat and Rev: positive modulators of human immunodeficiency virus gene expression.
    Rosen CA
    Gene Expr; 1991 May; 1(2):85-90. PubMed ID: 1820213
    [No Abstract]   [Full Text] [Related]  

  • 17. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
    Joshi P; Prasad VR
    J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards the selection of phosphorothioate aptamers optimizing in vitro selection steps with phosphorothioate nucleotides.
    Andreola ML; Calmels C; Michel J; Toulmé JJ; Litvak S
    Eur J Biochem; 2000 Aug; 267(16):5032-40. PubMed ID: 10931185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule.
    Lisziewicz J; Zeng G; Gratas C; Weinstein JN; Lori F
    Hum Gene Ther; 2000 Apr; 11(6):807-15. PubMed ID: 10779158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.